{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T16:33:37Z","timestamp":1793291617422,"version":"4.5.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Prostate Cancer Prostatic Dis"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1038\/s41391-026-01146-z","type":"journal-article","created":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T18:37:05Z","timestamp":1786732625000},"page":"1028-1035","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Utilization patterns of second-generation androgen receptor pathway inhibitors as first-line therapy for prostate cancer in the United States"],"prefix":"10.1038","volume":"29","author":[{"given":"Aidan S.","family":"Weitzner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soum D.","family":"Lokeshwar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-7086-3818","authenticated-orcid":false,"given":"Craig","family":"Cronin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-0790-4052","authenticated-orcid":false,"given":"Achyutha","family":"Kodavatikanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Korn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1679-2682","authenticated-orcid":false,"given":"Joseph G.","family":"Cheaib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuo Tony","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9495-6983","authenticated-orcid":false,"given":"Nirmish","family":"Singla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,14]]},"reference":[{"key":"1146_CR1","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1097\/JU.0000000000003452","volume":"209","author":"W Lowrance","year":"2023","unstructured":"Lowrance W, Dreicer R, Jarrard DF, Scarpato KR, Kim SK, Kirkby E, et al. Updates to Advanced Prostate Cancer: AUA\/SUO Guideline (2023). J Urol. 2023;209:1082\u201390.","journal-title":"J Urol"},{"key":"1146_CR2","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1001\/jama.2025.0228","volume":"333","author":"R Raychaudhuri","year":"2025","unstructured":"Raychaudhuri R, Lin DW, Montgomery RB. Prostate Cancer: A Review. JAMA. 2025;333:1433\u201346.","journal-title":"JAMA"},{"key":"1146_CR3","doi-asserted-by":"publisher","first-page":"4717","DOI":"10.1158\/1078-0432.CCR-19-3835","volume":"26","author":"M Brave","year":"2020","unstructured":"Brave M, Weinstock C, Brewer JR, Chi D-C, Suzman DL, Cheng J, et al. An FDA Review of Drug Development in Nonmetastatic Castration-resistant Prostate Cancer. Clin Cancer Res. 2020;26:4717\u201322.","journal-title":"Clin Cancer Res"},{"key":"1146_CR4","doi-asserted-by":"publisher","first-page":"2974","DOI":"10.1200\/JCO.19.00799","volume":"37","author":"AJ Armstrong","year":"2019","unstructured":"Armstrong AJ, Szmulewitz RZ, Petrylak DP, Holzbeierlein J, Villers A, Azad A, et al. ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer. J Clin Oncol. 2019;37:2974\u201386.","journal-title":"J Clin Oncol"},{"key":"1146_CR5","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1056\/NEJMoa1903307","volume":"381","author":"KN Chi","year":"2019","unstructured":"Chi KN, Agarwal N, Bjartell A, Chung BH, Pereira de Santana Gomes AJ, Given R, et al. Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer. N Engl J Med. 2019;381:13\u201324.","journal-title":"N Engl J Med"},{"key":"1146_CR6","doi-asserted-by":"publisher","first-page":"4271","DOI":"10.1200\/JCO-24-01798","volume":"42","author":"F Saad","year":"2024","unstructured":"Saad F, Vjaters E, Shore N, Olmos D, Xing N, Pereira de Santana Gomes AJ, et al. Darolutamide in Combination With Androgen-Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer From the Phase III ARANOTE Trial. J Clin Oncol. 2024;42:4271\u201381.","journal-title":"J Clin Oncol"},{"key":"1146_CR7","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1016\/S1470-2045(21)00402-2","volume":"22","author":"F Saad","year":"2021","unstructured":"Saad F, Efstathiou E, Attard G, Flaig TW, Franke F, Goodman OB, et al. Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): a randomised, placebo-controlled, double-blind, multinational, phase 3 study. Lancet Oncol. 2021;22:1541\u201359.","journal-title":"Lancet Oncol"},{"key":"1146_CR8","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1634\/theoncologist.2015-0166","volume":"20","author":"Y-M Ning","year":"2015","unstructured":"Ning Y-M, Brave M, Maher VE, Zhang L, Tang S, Sridhara R, et al. U.S. Food and Drug Administration Approval Summary: Enzalutamide for the Treatment of Patients With Chemotherapy-Na\u00efve Metastatic Castration-Resistant Prostate Cancer. Oncologist. 2015;20:960\u20136.","journal-title":"Oncologist"},{"key":"1146_CR9","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1056\/NEJMoa1815671","volume":"380","author":"K Fizazi","year":"2019","unstructured":"Fizazi K, Shore N, Tammela TL, Ulys A, Vjaters E, Polyakov S, et al. Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer. N Engl J Med. 2019;380:1235\u201346.","journal-title":"N Engl J Med"},{"key":"1146_CR10","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1056\/NEJMoa1715546","volume":"378","author":"MR Smith","year":"2018","unstructured":"Smith MR, Saad F, Chowdhury S, Oudard S, Hadaschik BA, Graff JN, et al. Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer. N Engl J Med. 2018;378:1408\u201318.","journal-title":"N Engl J Med"},{"key":"1146_CR11","doi-asserted-by":"publisher","unstructured":"Halabi S, Jiang S, Terasawa E, Garcia-Horton V, Ayyagari R, Waldeck AR, et al. Indirect Comparison of Darolutamide versus Apalutamide and Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer. J Urol 2021. https:\/\/doi.org\/10.1097\/JU.0000000000001767.","DOI":"10.1097\/JU.0000000000001767"},{"key":"1146_CR12","doi-asserted-by":"publisher","first-page":"e2025826","DOI":"10.1001\/jamanetworkopen.2020.25826","volume":"3","author":"ZW Myint","year":"2020","unstructured":"Myint ZW, Momo HD, Otto DE, Yan D, Wang P, Kolesar JM. Evaluation of Fall and Fracture Risk Among Men With Prostate Cancer Treated With Androgen Receptor Inhibitors. JAMA Netw Open. 2020;3:e2025826.","journal-title":"JAMA Netw Open"},{"key":"1146_CR13","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1001\/jamaoncol.2024.5661","volume":"11","author":"B Gyawali","year":"2025","unstructured":"Gyawali B, Jung EH, Mooney H, Avorn J, Kesselheim AS. Government Funding for the Development of Enzalutamide. JAMA Oncol. 2025;11:182\u20133.","journal-title":"JAMA Oncol"},{"key":"1146_CR14","doi-asserted-by":"publisher","first-page":"e297","DOI":"10.1371\/journal.pmed.0040297","volume":"4","author":"JP Vandenbroucke","year":"2007","unstructured":"Vandenbroucke JP, von Elm E, Altman DG, G\u00f8tzsche PC, Mulrow CD, Pocock SJ, et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): Explanation and Elaboration. PLoS Med. 2007;4:e297.","journal-title":"PLoS Med"},{"key":"1146_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-018-4166-3","volume":"18","author":"MEV Caram","year":"2018","unstructured":"Caram MEV, Estes JP, Griggs JJ, Lin P, Mukherjee B. Temporal and geographic variation in the systemic treatment of advanced prostate cancer. BMC Cancer. 2018;18:258.","journal-title":"BMC Cancer"},{"key":"1146_CR16","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1080\/14796694.2025.2480050","volume":"21","author":"J Hafron","year":"2025","unstructured":"Hafron J, Hong A, Ryan MJ, Romdhani H, Kinkead F, Flanders SC, et al. Study of persistence and adherence to ADT in prostate cancer: relugolix, degarelix, and GnRH agonists in the US. Future Oncol. 2025;21:1219\u201330.","journal-title":"Future Oncol"},{"key":"1146_CR17","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","volume":"367","author":"HI Scher","year":"2012","unstructured":"Scher HI, Fizazi K, Saad F, Taplin M-E, Sternberg CN, Miller K, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367:1187\u201397.","journal-title":"N Engl J Med"},{"key":"1146_CR18","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1056\/NEJMoa1903835","volume":"381","author":"ID Davis","year":"2019","unstructured":"Davis ID, Martin AJ, Stockler MR, Begbie S, Chi KN, Chowdhury S, et al. Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer. N Engl J Med. 2019;381:121\u201331.","journal-title":"N Engl J Med"},{"key":"1146_CR19","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1056\/NEJMoa2003892","volume":"382","author":"Sternberg","year":"2020","unstructured":"Sternberg, Fizazi CN, Saad K, Shore F, Giorgi ND, De U, et al. Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer. N Engl J Med. 2020;382:2197\u2013206.","journal-title":"N Engl J Med"},{"key":"1146_CR20","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1038\/s41391-024-00829-9","volume":"27","author":"M Shelan","year":"2024","unstructured":"Shelan M, Achard V, Appiagyei F, Mose L, Zilli T, Fankhauser CD, et al. Role of enzalutamide in primary and recurrent non-metastatic hormone sensitive prostate cancer: a systematic review of prospective clinical trials. Prostate Cancer Prostatic Dis. 2024;27:422\u201331.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"1146_CR21","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s11523-023-00959-5","volume":"18","author":"SCR Williams","year":"2023","unstructured":"Williams SCR, Mazibuko N, O\u2019Daly O, Zurth C, Patrick F, Kappeler C, et al. Comparison of Cerebral Blood Flow in Regions Relevant to Cognition After Enzalutamide, Darolutamide, and Placebo in Healthy Volunteers: A Randomized Crossover Trial. Target Oncol. 2023;18:403\u201313.","journal-title":"Target Oncol"},{"key":"1146_CR22","doi-asserted-by":"publisher","first-page":"1892","DOI":"10.1007\/s10147-020-01777-9","volume":"25","author":"K Mori","year":"2020","unstructured":"Mori K, Mostafaei H, Pradere B, Motlagh RS, Quhal F, Laukhtina E, et al. Apalutamide, enzalutamide, and darolutamide for non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis. Int J Clin Oncol. 2020;25:1892\u20131900.","journal-title":"Int J Clin Oncol"},{"key":"1146_CR23","doi-asserted-by":"publisher","first-page":"e2429783","DOI":"10.1001\/jamanetworkopen.2024.29783","volume":"7","author":"DJ George","year":"2024","unstructured":"George DJ, Morgans AK, Constantinovici N, Khan N, Khan J, Chen G, et al. Androgen Receptor Inhibitors in Patients With Nonmetastatic Castration-Resistant Prostate Cancer. JAMA Netw Open. 2024;7:e2429783.","journal-title":"JAMA Netw Open"},{"key":"1146_CR24","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.eururo.2024.03.036","volume":"86","author":"F Saad","year":"2024","unstructured":"Saad F, Hussain MHA, Tombal B, Fizazi K, Sternberg CN, Crawford ED, et al. Deep and Durable Prostate-specific Antigen Response to Darolutamide with Androgen Deprivation Therapy and Docetaxel, and Association with Clinical Outcomes for Patients with High- or Low-volume Metastatic Hormone-sensitive Prostate Cancer: Analyses of the Randomized Phase 3 ARASENS Study. Eur Urol. 2024;86:329\u201339.","journal-title":"Eur Urol"},{"key":"1146_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2025.1680002","volume":"13","author":"Y Yang","year":"2025","unstructured":"Yang Y, Chen Y-Q, Huang L-Z, Chen Y. Cost-effectiveness analysis of second-generation androgen receptor antagonists for the treatment of metastatic hormone-sensitive prostate cancer. Front Public Health. 2025;13:1680002.","journal-title":"Front Public Health"},{"key":"1146_CR26","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1093\/jnci\/djad135","volume":"115","author":"M Yoo","year":"2023","unstructured":"Yoo M, Nelson RE, Haaland B, Dougherty M, Cutshall ZA, Kohli R, et al. Cost-effectiveness analysis of 7 treatments in metastatic hormone-sensitive prostate cancer: a public-payer perspective. J Natl Cancer Inst. 2023;115:1374\u201382.","journal-title":"J Natl Cancer Inst"},{"key":"1146_CR27","doi-asserted-by":"publisher","first-page":"3325","DOI":"10.1002\/cam4.2092","volume":"8","author":"JL Beebe-Dimmer","year":"2019","unstructured":"Beebe-Dimmer JL, Ruterbusch JJ, Cooney KA, Bolton A, Schwartz K, Schwartz AG, et al. Racial differences in patterns of treatment among men diagnosed with de novo advanced prostate cancer: A SEER-Medicare investigation. Cancer Med. 2019;8:3325\u201335.","journal-title":"Cancer Med"},{"key":"1146_CR28","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1200\/OP-25-00050","volume":"21","author":"SV Carlsson","year":"2025","unstructured":"Carlsson SV, Barata PC, Bryce AH, George DJ, Gillessen S, Loeb S, et al. Prostate Cancer Foundation White Paper on Combination Therapy for Metastatic Hormone-Sensitive Prostate Cancer. JCO Oncol Pr. 2025;21:1240\u20136.","journal-title":"JCO Oncol Pr"},{"key":"1146_CR29","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1001\/jamaoncol.2022.6296","volume":"9","author":"CE Carroll","year":"2023","unstructured":"Carroll CE, Landrum MB, Wright AA, Keating NL. Adoption of Innovative Therapies Across Oncology Practices-Evidence From Immunotherapy. JAMA Oncol. 2023;9:324\u201333.","journal-title":"JAMA Oncol"},{"key":"1146_CR30","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1056\/NEJMoa2119115","volume":"386","author":"MR Smith","year":"2022","unstructured":"Smith MR, Hussain M, Saad F, Fizazi K, Sternberg CN, Crawford ED, et al. Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer. N Engl J Med. 2022;386:1132\u201342.","journal-title":"N Engl J Med"}],"container-title":["Prostate Cancer and Prostatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41391-026-01146-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41391-026-01146-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41391-026-01146-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T16:03:01Z","timestamp":1793289781000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41391-026-01146-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["1146"],"URL":"https:\/\/doi.org\/10.1038\/s41391-026-01146-z","relation":{},"ISSN":["1365-7852","1476-5608"],"issn-type":[{"value":"1365-7852","type":"print"},{"value":"1476-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"18 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"This study used retrospective, deidentified data from the Merative MarketScan database in accordance with Section \u00a7164.514(b)(1) of the Health Insurance Portability and Accountability Privacy Rule. As this study included analysis of de-identified, administrative claims data, it did not constitute human subjects research and was deemed exempt from institutional review or informed consent. All methods were performed in accordance with the relevant guidelines and regulations.","order":2,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Ethics"}}]}}